• The SaaS sector is projected to grow by $99.99 billion between 2021 and 2025
• It is also projected that in the next few years, SaaS tools will exceed 50,000 globally
• Infobird is positioning itself to capitalize on this growth through innovation and its line of AI-powered solutions
• Its launch and successful implementation of the Intelligent Quality Inspection SaaS in July 2021 marks the company’s commitment to innovation and solving customer needs
• Infobird also continues to set itself apart by involving its customers in the development of Intelligent Quality Inspection SaaS

Experts project that within the next few years, Software-as-a-Service (“SaaS”) tools will exceed 50,000 globally (https://ibn.fm/mvxSt). They note that most mid-market enterprises will use dozens of tools for various functions, with smaller companies using even more to cover every function. They acknowledge and confirm the growing popularity of SaaS along with the unique value proposition it offers to businesses around the world. This sector is projected to grow by $99.99 billion between 2021 and 2025, and Infobird (NASDAQ: IFBD) is positioning itself to make the most out of this growth (https://ibn.fm/L1DPg).

Infobird is a SaaS company with a focus on the Chinese market, specifically for the finance segment. It offers Artificial intelligence (“AI”)-enabled end-to-end customer engagement solutions for businesses within this market. The company is constantly innovating and redefining itself. So far, it has 70 Intellectual Property (“IP”) rights developed under its cloud-native architecture and AI technologies. This is aiding with the company’s growth and the expansion of its customer base and market reach.

In July 2021, Infobird announced the successful implementation of its Intelligent Quality Inspection SaaS with one of the largest fintech companies in China (https://ibn.fm/DGIyL). (https://ibn.fm/2xHV3). (https://ibn.fm/dn5Ev). (https://ibn.fm/L2JEo). This Intelligent Quality Inspection SaaS was explicitly designed to initiate intelligent management and operations for clients’ customer service platforms. Additionally, it lays the foundation for further upgrades of the clients’ customer service, a massive milestone for Infobird.

With innovations and new product additions such as these, Infobird is slowly but surely, asserting its position as a leader in the Chinese, global SaaS markets. It is also positioning itself to capitalize on the imminent growth of this sector while making the most out of the various available opportunities.

One thing that sets Infobird apart from its competitors is its client involvement when developing Intelligent Quality Inspection SaaS. The company is committed to tailoring the service to the clients’ needs. This often means involving them in the entire process, understanding how they work and function, and their objectives for the software and their business. Infobird goes out of its way to research and analyze its clients’ customer service business scenarios, thereby building a flexible multi-dimensional quality inspection model that is guaranteed to work and guaranteed to be of value to the client (https://ibn.fm/jyv0c). The company also understands that offering a great SaaS experience is more than simply creating the system and getting it to work. Instead, it takes it a step further by conducting customer service training and management work, a move aimed at achieving greater productivity, efficiency, and success.

Infobird is an enterprise that understands the potential of the SaaS market, hence its commitment to innovation and solving customer needs and requirements. With its research and development, the company is asserting itself as the industry leader while pushing the next frontier in SaaS, AI, and a fusion of the two.

For more information, visit the company’s website at www.Infobird.com/en/index.html.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer

ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com

ChineseWire is part of the InvestorBrandNetwork.

A recently published review has discovered that considering genetic data for individuals who are suffering from drug-resistant focal epilepsy has led to the definition of novel illness entities and enhanced clinical decision making. Drug-resistant focal epilepsy, as defined by the International League Against Epilepsy, usually occurs when an individual has failed to stay free of seizures with sufficient trials of 2 ASMs (anti-seizure medication). The disease is often caused by brain lesions such as glioneural tumors.

These drugs must have been specifically chosen for the individual’s type of seizures and tried in combination with other seizure medications or on their own. Epilepsy surgery can be a curative treatment option for some patients.

Physicians usually identify these lesions using intracerebral electroencephalogram and magnetic resonance imaging (“MRIs”). However, these techniques lack the accuracy and specificity required to the lesions.

This led the research team to develop a tumor classifier that utilizes epigenetic profiling. The brain tumor classifier utilizes CpG sites in identifying different tumor groups and has shown to be useful in recognizing multiple tumor entities, including isomorphic diffuse glioma, glioneural tumors with nuclear clusters and primary mismatch repair-deficient IDH-mutant astrocytoma. These lesions, among many others, are difficult to diagnose without using molecular approaches and are usually morphologically heterogeneous.

In their report, the authors of the review discuss the different types of lesions that are linked to particular molecular markers. These lesions are brought about by a combination of germline and somatic variants, and they often impact glycosylation, receptor tyrosine kinase/mitogen-activate protein kinase (RTK/MPAK) signaling and mechanistic target of rapamycin (“mTOR”) signaling. These lesions can also be evaluated using cell-free DNA, without conducting a biopsy. This can be done using a cerebrospinal fluid sample that has been collected by a dural puncture.

However, the authors note in their report that this particular technique may require additional validation. Methylation profiles evaluated from peripheral blood can also be used to diagnose epilepsy, but studies on methylation in epilepsy are scarce at the moment. In addition, more studies and samples are required to assess the potential of DNA methylation in drug-resistant focal epilepsy.

The authors of the review conclude that molecular approaches are altering the diagnostic process for individuals suffering from this particular type of epilepsy. They note that the approaches could potentially be used by physicians to accurately give diagnoses of causal lesions based off of data collected using procedures that are less-invasive.

The neurology diagnosis segment is growing rapidly, and the improved diagnostic devices marketed by companies such as Brain Scientific Inc. (OTCQB: BRSF) are likely to enable earlier detection of conditions which compromise neurological health.

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols
• AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream
• AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness
• The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of its U.S. operations.

The US and China based cancer screening technology innovator AnPac Bio-Medical Science (NASDAQ: ANPC) is advancing its operations in the United States, announcing Aug. 17 that accomplished bio-medical scientist Dr. Sunil Pandit has been named the CEO of the company’s U.S. operations, AnPac Technology USA Co., Ltd. (or AnPac Bio US).

Dr. Pandit will lead the company’s strategic efforts to increase adoption of AnPac Bio’s early cancer detection technology — the pioneering Cancer Differentiation Analysis (“CDA”) platform that is the company’s core product and a proven revenue generator.

“AnPac Bio has been recognized for its innovation and leadership in the field of early cancer screening and detection,” Pandit stated in the news release announcing his appointment (https://ibn.fm/KSjtr). “I am confident that given AnPac Bio’s strong innovation and superiority of its novel cancer screening products, we will win customers and market share and become a top tier cancer screening and early detection company in the U.S. in the future.”

Blood sample-based cancer screenings generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (ct-DNA), circulating in the blood stream to determine if a cancer exists and is spreading. The novelty of AnPac Bio’s early detection technology is looking for signals to help it assess the risk of cancer occurring before a tumor has developed. In addition to CDA technology’s ability to detect early cancer risk, this technology also has unique advantages in detecting multiple cancer types and is highly cost effective.

“Recent studies have shown that there is a correlation between certain biophysical properties, including acoustical, electrical, magnetic, nano-mechanical and optical properties, and cancer occurrence. These studies have revealed that biophysical properties could be important non-genetic aspects of the micro-environment regulating the balance between normal cell growth and carcinogenesis (cancerous growth), which may lead to cancer occurrence,” the company’s Prospectus Supplement filed with the U.S. Securities and Exchange Commission last month states (https://ibn.fm/GfDKx).

“Our proprietary CDA device uses an integrated sensor system to detect certain biophysical signals in blood samples,” the supplement adds. “After collecting data on these signals, we use our CDA technology and proprietary algorithm to measure and analyze these signals at multiple biological levels (including the protein, cellular and molecular levels) and with multiple parameters (including the overall CDA value, the PTF value and the CTF value).”

PTF and CTF values refer to the Protein Tumor Factor and Cellular Tumor Factor data sets and is proprietary to Anpac Bio CDA technology.

Patent applications for the apparatus and methods behind the CDA detection technology began about a decade ago and in 2015 the company performed its first commercial CDA-based test, with the capacity to screen for 16 different types of cancers using a multi-level, multi-parameter approach, well before its current competitors. The company now is able to detect the risk of 26 different cancer types with high sensitivity and specificity. In 2020, despite the global pandemic, the Company’s overall revenue increased by 89.1%, to $3.2 million. The company also pre-announced recently that its test volume in the first half of 2021 has increased 110% over the same period in 2020.

For more information, visit the company’s website at www.AnPacBio.com.

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

America’s increasingly liberal attitude regarding cannabis consumption has started to impact workplace policies. For decades, both federal and state law outlawed cannabis, which was in turn mirrored in workplace policies across the country. Most employers had a zero-tolerance policy on cannabis, with some even requiring regular drug tests and firing employees who failed. But with cannabis reform sweeping the nation, companies are starting to reconsider their drug policies.

This became increasingly clear when Amazon, the largest player in the e-commerce market with 1.3 million employees around the world, announced that it would cease testing job seekers for marijuana. A lot of businesses had been revising their drug policies in the wake of increased cannabis legalization, but Amazon’s announcement showed that the cannabis reform movement was gaining major traction. However, president and CEO of the Illinois Chamber of Commerce Todd Maisch says that while plenty of companies are relaxing their attitudes toward cannabis, there’s still plenty that aren’t.

No business wants their employees to be impaired while on the job, he says, but for a lot of them, the days of random drug tests are drawing to a close. It ultimately depends on the type of business, with some having a lot of flexibility regarding their drug policies and others being unwilling and in most cases unable to relax their drug policies. For instance, businesses in construction whose employees have to use heavy machinery have to maintain a drug-free policy to keep their staff safe while on-site as well as to limit their culpability in case an impaired employee is involved in a workplace accident.

Additionally, entities and individuals that have contracts with the federal government are required to stay clear of all drugs, even the ones that are state legal, because drug use is outlawed by federal law. As such, Maisch says, the evolution of workplace policies regarding cannabis consumption has had two approaches, with some companies adapting to the changing times and others digging their heels in and adhering to federal policy on cannabis. Fortunately for cannabis-reform proponents, current events have influenced how employers treat cannabis.

The pandemic had a historic effect on the job market, forcing a lot of industries to slow down in the wake of lockdown orders and promoting a work-from-home culture. More than a year after the coronavirus struck and as the world started opening up, people began questioning the job market and demanding fair pay and benefits. This has led to a labor shortage of the likes we have never seen before, and employers are scrambling to hire employees who are willing to join their ranks.

Thus, employers across the country are ready to loosen their workplace policies, especially regarding off-duty cannabis use, Maisch says. This easing of restrictions is likely to open up even more the clientele for cannabis products made by companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) since more people will be willing to consider cannabis usage during their off-duty hours.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

NetworkNewsWire Editorial Coverage: An old investing proverb states “the trend if your friend.” Tested and proven through time, the proverb rarely does an investor wrong. To that point, two emerging trends that should be commanding attention are plant-based foods and food delivery. Both were disrupted during the COVID-19 pandemic but in slightly different ways as consumers became more in tune with their bodies while having to cope with shuttered restaurants amid global lockdowns and social-distancing mandates. With the coronavirus slowly slipping into the rear mirror, these markets should continue their upward treks undergirded by consumers adopting healthier, more convenient lifestyles. At the intersection of plant-based foods and food delivery is PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (Profile), a company on a mission to not just be a brand but also a lifestyle, partner to all brands, and the digital face of the entire plant-based community. Others looking to capitalize on the trend away from animal-based foods include Beyond Meat Inc. (NASDAQ: BYND), Tattooed Chef Inc. (NASDAQ: TTCF), Amazon.com Inc. (NASDAQ: AMZN) and Oatly Group AB (NASDAQ: OTLY).

• The global market for plant-based foods could see fivefold growth by 2030, according to a recent Bloomberg article.
• PlantX Life is a first mover combining a leading e-commerce platform selling exclusively plant-based products with a meal preparation and delivery service.
• Delivery of online sales of prepared vegan meals and drinks began in January and have since expanded in Canada and begun in Los Angeles.
• PlantX works with sports stars Venus Williams and Justin Fields as ambassadors and world renown vegan chef Matthew Kenney as its chief culinary officer.

Double-Digit Growth Trends

It wasn’t long ago that faux meat was scoffed at — that is until Beyond Meat and rival Impossible Burger became international brands, landing on menus and in refrigerated coolers at leading stores and restaurants and generating valuations into the billions of dollars. The trend toward plant-based meat hiccupped during the coronavirus pandemic in 2020 insomuch that restaurant sales fell while the U.S. plant-based food industry grew as a whole. Analysts at IMARC note that the global plant-based food market reached $35.6 billion in 2020, while forecasting double-digit annual growth of 10.4% through 2026, which equates to near doubling for the market to $64.5 billion.

The global market for plant-based foods could see fivefold growth by 2030, according to a recent Bloomberg article. That increase is helped by rising consumer demand for sustainable products. “Sales of plant-based dairy and meat alternatives reached $29.4 billion in 2020, and could increase to $162 billion by 2030, comprising 7.7% of the global protein market,” the article stated.

“Meat and dairy substitutes are marketed as healthier and more sustainable than the products from animals that they aim to replace,” the article continued. “They’re getting popular just as consumers become more conscious of the environmental footprint of food, and aim for healthier eating.” The forecasts indicate that consumers are increasingly moving towards vegan diets and ditching long lines in favor of ordering online and eating premium food without leaving the comforts of home.

These aren’t exactly new trends; they were already emerging trends that accelerated during the pandemic. PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is an early mover in the space as the first public company focusing on the plant-based e-commerce sector, in addition to a network of brick-and-mortar retail locations. The company is similar to a specialized Amazon.com with added features. Since inception in February 2020, the company has moved with purpose toward a core objective of becoming the most trusted and convenient destination for people living plant-based lives. Brands under the PlantX umbrella include XFood, Bloombox Club, Little West, New Deli, Locavore Bar & Grill and Cloudburst Café.

The PlantX platform is robust, offering consumer packaged goods for plant-based lifestyles, an integrated home-delivery system for thousands of vegan grocery items, meals, wines, beers recipes, indoor plants and more, as well as an online community where like-minded individuals connect from different parts of the world. PlantX has built trust as a premier e-commerce platform and manufacturer through partnerships with venerable restaurants, nutritionists, chefs and brands.

PlantX Star-Studded Lineup

PlantX offers more than 5,000 plant-based consumer products available for home delivery ranging from foodstuffs, vitamins, cosmetics, pet food and more. In a move of marketing genius, the company partnered with sports superstars and plant-based lifestyle advocates as brand ambassadors, including tennis star Venus Williams, Chicago Bears quarterback Justin Fields, extreme skier Nick McNutt and extreme mountain biker Rémy Métailler. These professional athletes and personalities share and promote their favorite products from individual juices to complete meals for fans and PlantX shoppers to follow.

PlantX’s XFood lineup of innovative plant-based meals are designed by restaurateur and famous vegan chef Matthew Kenney, who is also the company’s chief culinary officer. Kenney is world renowned as the chef behind more than 40 vegan restaurants, including Double Zero, Plant Food and Wine, Baia, Alibi and Sutra. In order to spearhead the movement towards vegan home-meal delivery, PlantX partnered with Vancouver-based food tech company UpMeals.

Expansion in Canada, Launched in U.S.

PlantX’s meal-delivery plan was first launched in Canada in January 2021. Customers could order a la carte, three-day or five-day meal plans that include breakfast, lunch and dinner as part of a “set it and forget it” subscription service. Meals were shipped once a week. By June, the company responded to growing demand in Canada by adding a second delivery day each week for its subscription meal programs.

In July, the meal delivery service was launched in the United States, with packaged meals prepared at PlantX’s ghost kitchen in Los Angeles first reaching American customers on August 9. The three-day and five-day meal plans retail for $99.95 and $174.95, respectively, with the company offering a 10% discount for first-time customers. Meals are currently available in Southern California within a 60-mile radius of Los Angeles, which covers a population of roughly 19 million people.

Going forward, PlantX intends to steadily add new markets to eventually service the whole country. The decision to launch in the populous Greater LA region could prove prescient to build brand recognition and leverage its team and operational structure, considering LA was ranked the second most vegetarian- and vegan-friendly city in America by WalletHub.

PlantX Teams with Disney

Companies are often best known for the company that they keep, and PlantX is checking the boxes. This month, the company’s Bloombox Club Limited business, a U.K.-based e-commerce platform that sells and delivers indoor plants and accessories (pots, watering cans, misters, etc.), partnered with the Walt Disney Company. Per the pact, the new partners are working together to promote Bloombox products and celebrate the release of Disney’s new film, “Jungle Cruise,” which has launched in theaters and on Disney+.  Starring Dwayne “The Rock” Johnson and Emily Blunt, the film reeled in more than $90 million in theater and streaming sales during opening weekend early this month.

The co-branded campaign will include Bloombox promoting the film via a new Amazonian exotic plant collection. Among other things, the promotion will also include a social media campaign and a treasure hunt on the Bloombox website.

Meat Alternatives Are Here to Stay

Billions of dollars in investment are going into the plant-based food space as companies and investors alike recognize the market opportunity. The secret is out that plant-based foods aren’t some newfangled concoctions swirled up in beakers by chemists in lab. The science is sound, the taste and texture are comparable to their animal counterparts, and the recipes are designed by world-class chefs.

Beyond Meat Inc. (NASDAQ: BYND) is one of the fastest-growing food companies in the United States, offering a portfolio of revolutionary plant-based proteins made from simple ingredients without GMOs, bioengineered ingredients, hormones, antibiotics, or cholesterol. This month, Beyond Meat teamed up with Pizza Hut to add plant-based pepperoni to the menu developed jointly by both companies’ culinary teams. Made from rice and peas, Beyond Pepperoni reportedly crisps like traditional meat pepperoni with zero cholesterol or animal products and is being introduced for a limited time at 70 locations in five cities.

Tattooed Chef Inc. (NASDAQ: TTCF) signature products include ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, and cauliflower pizza crusts found in leading food stores throughout the United States. This month the company released results from the second quarter, which spoke to growing demand for its products. Revenue was $50.7 million, a 45.9% increase compared to $34.8 million in the prior year period, including Tattooed Chef-branded product revenue climbing to $33.1 million, an increase of 62.3% compared to $20.4 million in the prior year period.

Amazon.com Inc. (NASDAQ: AMZN) is an e-commerce giant that sells tens of thousands of plant-based products. Additionally, Amazon has a direct interest in the wellness space since it bought Whole Foods Market for $13.4 billion in 2017. Whole Foods last year debuted a plant-based dairy alternative product (read as “plant-based milk”) that was developed by NotCo, a company that was backed by venture capital including Bezos Expeditions, a business of Amazon CEO Jeff Bezos.

Oatly Group AB (NASDAQ: OTLY) is the world’s original and largest oat drink company. Oatly has branched out into a portfolio of oat-based dairy alternatives including milk, ice cream, yogurt, cooking creams and spreads. The Sweden-based company has its products in more than 20 countries and recently increased capacity at its facility in Ogden, Utah, to support an acceleration in consumer demand.

The investment community will surely be watching for Impossible Burger to pull the trigger with an initial public offering, as a signal that Wall Street appetite is growing again for plant-based food companies. Safe to say, that plant-based food and drinks aren’t going anywhere but up, as they become staples in the lives of younger generations, who, by the way, like the food brought right to their door.

For more information about PlantX Life Inc., please visit PlantX Life Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 50+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

• Lexaria Bioscience is a drug delivery technology innovator whose flagship technology, DehydraTECH(TM), provides a means of enhancing substances’ delivery time to increase their effectiveness without adverse effects
• A new podcast by NetworkNewsAudio highlights DehydraTECH’s successes in trials that measure blood pressure reduction using DehydraTECH-enhanced CBD in comparison with generic controls
• The DehydraTECH technology is also being analyzed for effectiveness in combatting inflammatory conditions, viral illnesses and alternatives to the lung-harming effects of smoking
• The company’s most recent filing with the SEC notes that its revenues more than doubled between May 2020 and May 2021, driven largely by product sales and licensing agreements

A new podcast highlights the effectiveness enhancement efforts by technology innovator Lexaria Bioscience (NASDAQ: LEXX) for treating high blood pressure (hypertension), a key risk factor for both heart disease and stroke that is common in the world’s adult populations, including in the United States.

The podcast (https://cnw.fm/Zf5i6) reviews many important entrepreneurial tips to business owners from Lexaria CEO Chris Bunka. It also notes that nearly half of all Americans have high blood pressure but only about 24 percent of those afflicted with it — many of whom are younger than 40. One of the most insidious aspects of high blood pressure is that, like diabetes, the damage they can cause is often already done by the time they are diagnosed, a reason India’s government recently announced that the health department has begun screening government employees for the conditions in all departments, for example (https://cnw.fm/M6leX).

Lexaria’s patented DehydraTECH(TM) technology is designed to enhance substances such as pharmaceutical drugs into a more readily bioavailable form that speeds up their time to effective use. Clinical trials have been analyzing its ability to accomplish this transformation without causing changes that adversely interfere with the drugs’ intended use, such as by inadvertently creating new molecular entities NMEs that would require more complex new regulatory approvals (https://cnw.fm/KUX1Y).

“Just last month, Lexaria announced that a human clinical study using DehydraTECH technology demonstrated a rapid and sustained drop in blood pressure along with excellent tolerability,” the podcast states. “Initial results show that blood pressure was reduced across both male and female volunteers and was most pronounced in the first 10–50 minutes of the study treatment, reinforcing pre-existing findings demonstrating that DehydraTECH delivers superior performance over generic controls.”

The company’s focus on DehydraTECH is not only to produce a better solution for delivering blood pressure treatments, but also anti-virals that battle SARS-CoV-2/COVID-19, HIV and other illness-causing invaders.

DehydraTECH is also being looked at as a way of making nicotine orally ingestible at a level of quick absorption and efficacy superior to smoked and vaped drugs with the intent of creating a desirable and less harmful alternative to lung-harming inhalation of the substances (https://cnw.fm/AvPBf).

Last month Lexaria chose to delist its common shares from the Canadian Securities Exchange in order to focus on trading on the Nasdaq Capital Markets (Nasdaq ticker LEXX), where it has been seeing greater liquidity and can reduce the fees and managerial commitment that went into a dual listing (https://cnw.fm/w21tt).

The company’s July 10-Q filing with the Securities and Exchange Commission noted that revenues more than doubled between May 2020 and May 2021, driven by intermediate product sales of DehydraTECH-enabled powders that companies can purchase to include in their products and licensing fees arising from definitive agreements for the DehydraTECH technology (https://cnw.fm/aiviY).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

A nationally representative study that was recently conducted reports that about 29% of participants who had a suicide attempt history had achieved a state of complete mental health.

In order to make that determination, participants had to report high levels of psychological and social well-being in the last month, almost daily life satisfaction or happiness in the last month, and freedom from suicidality and mental ailments such as substance dependence and psychiatric disorders to be considered in complete mental health.

The study was published in the “Archives of Suicide Research.”

Prof. Esme Fuller-Thomson from the University of Toronto, the study’s lead author, stated that this was a hopeful discovery for people struggling with suicidal ideation. Fuller-Thomson, who is also the director of the Institute for Life Course and Aging, explained that the group’s discovery showed that a good number of people who had a history of suicide attempts went on to achieve high levels of psychological flourishing and happiness.

For their study, the scientists assessed a sample of more than 750 Canadians who had tried to commit suicide at a point in their lives. The researchers recruited the participants using data obtained from the Canadian Community Health Survey-Mental Health at Statistics Canada.

Assistant Prof. Philip Baiden, who was the study’s co-author, stated that the researchers discovered social support to be a primary factor in supporting the well-being of people with a history of suicide attempts. Baiden, who hails from the University of Texas at Arlington, added that the respondents who had an individual to confide in were more likely to be in complete mental health. Other factors that were linked to complete mental health included absence of insomnia and being free from chronic pain.

Ian Mahoney, another co-author, stated that the study also highlighted factors that acted as barriers to positive mental health outcomes after an individual had attempted to commit suicide. He noted that it was crucial to address modifiable factors, including chronic pain and insomnia, in order to support this population’s well-being.

The study also found that complete mental health was more prevalent among individuals with higher income and individuals who were older; women were also more prone to be categorized in complete mental health.

Another co-author of the study Andie MacNeil asserted that while remission from suicidal ideation was an essential factor in the recovery process, the study drew attention to the different mental health outcomes. He noted that the research also incorporated measures of psychological and social well-being that encouraged the use of a more holistic approach to an individual’s recovery from suicidality.

In case the suicidal ideation was the result of an underlying psychiatric condition, there is even more hope for the patients because several companies, including Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), are working to develop a new class of psychiatry medicines whose efficacy is likely to be greater than that of the existing medications, and that means one would have the causes of their condition addressed instead of only managing the symptoms.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

• “I’m looking forward to being a key player in [The Alkaline Water Company’s] continued success,” says O’Neal
• WTER’s Alkaline88(R) continues to be one of the most prominent growing premium functional waters in the category
• Investors believe that Alkaline88 is becoming a household name for premium waters and a go-to brand across America

After initially joining The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER) as an equity partner, board member and marquee brand ambassador for Alkaline88(R), basketball Hall of Famer and entertainment icon Shaquille O’Neal has invested an additional of $1.05 million in the alkaline water company. O’Neal and WTER chairman Aaron Keay made an equal investment in the company (https://cnw.fm/gSZ6P).

“I only invest in companies I believe in and products that I use,” said O’Neal. “Alkaline88 checks both boxes. We’ve got big plans for this company, and I’m looking forward to being a key player in its continued success.”

The company noted that O’Neal and Keay’s investments accounted for more than 40% of the entire nonbrokered private placement, which comprised 4,757,381 subscription receipts sold at $1.05 per receipt; the gross proceeds of the private placement totaled $4,995,250.05. According to the announcement, WTER anticipates using the proceeds to expand production capacity and for use as general working capital.

“Alkaline88 continues to be one of the most prominent growing premium functional waters in the category,” state Keay. “Having just reported another record year, the company could not be better positioned for aggressive growth throughout fiscal 2022 in multiple different sales channels. Leading this financing alongside Shaquille is not only an honor but an aligned testament to both our beliefs that Alkaline88 is becoming a household name for premium waters and a go-to brand across America.”

WTER president and CEO Ricky Wright noted that the company could not have found a better partner for Alkaline88 than O’Neal. “I can’t overstate how business-minded he is about the success of this company, and I believe that this investment emphasizes that point even more,” said Wright. “We’re absolutely thrilled to have him as the face of our company, but even more so to count him as a business partner.”

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked Clean Beverage label.

Recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors, with new flavors coming soon.

For more information, visit the company’s websites at www.TheAlkalineWaterCo.com and www.a88CBD.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

• China-based information technology company Infobird recently launched a WeChat call center designed to incorporate WeChat’s multi-channel functionality with Infobird’s SaaS platform for recruiting and retaining customers
• Infobird’s platform uses big data and AI to create “portraits” of consumers’ expectations and needs by analyzing input from multiple channels
• WeChat became the world’s largest standalone mobile app in 2018 with over 1 billion monthly active users of its messaging, social media and mobile payment services
• Infobird’s cloud computing and AI technologies have generated more than 70 proprietary licensing rights

The growth of China’s robust economic engine and the rapid modern development of the nation’s middle and upper-middle class societies in recent years has driven both domestic and foreign companies to seek out and court the hundreds of millions of Chinese consumers connected to the economy through technological tools (https://ibn.fm/B5uv6).

Companies seeking to use their resources in the most effective manner possible to acquire and retain consumers have turned to the automated, intelligent solutions big data and artificial intelligence (“AI”) can provide through the software-as-a-service (SaaS) market. Chinese SaaS innovator Infobird (NASDAQ: IFBD) is making a name for itself through its recent Nasdaq debut as well as a growing number of retail agreements that use its technology, and on July 26 the company announced its next step with the launch of its WeChat call center.

The WeChat call center is designed to help businesses build an automated and personalized private domain traffic operation platform that will help the B2C clients achieve major upgrades while drawing on the the advantages of the powerful WeChat ecosystem for interacting with customers.

WeChat is a Chinese multi-channel messaging, social media and mobile payment app that became the world’s largest standalone mobile app in 2018 with over 1 billion monthly active users (https://ibn.fm/n9wNn). Infobird’s WeChat call center brings the functionality of corporate WeChat to Infobird’s multi-channel customer interaction platform with “an exclusive private domain traffic ecosystem for enterprises through four steps” that include attracting customers, retaining customers, keeping customers actively engaged and successfully managing the customer service interactions of company personnel, according to the Google translation of the company’s Chinese news release (https://ibn.fm/pLmqK).

Using private domain traffic for the development of long-term customer relationships has become a necessary path to company growth. The SaaS industry in China was valued at $3.3 billion last year after growing 43.5 percent from the year before (https://ibn.fm/dJT7T).

Infobird has created a single platform to meet the needs of consumers and businesses by using big data and AI to analyze input from multiple channels and then generate portraits or profiles that represent each user, their expectations and their needs.

The platform provides the means for companies to understand their customers more completely and accurately, which makes it possible for the companies to employ precision marketing in e-commerce and physical stores, incorporating Infobird’s product into the companies’ infrastructure in an essentially seamless manner.

Infobird is focused on SMEs, demystifying software and automation in business processes. The advent of the COVID-19 pandemic last year expanded remote-work demands exponentially for businesses from small family operations to large corporations, and Internet cloud-based technology has stepped in to fill the need.

For more information, visit the company’s website at www.Infobird.com/en/index.html.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About ChineseWire

ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.

For more information, please visit https://www.ChineseWire.com

Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: http://IBN.fm/Disclaimer

ChineseWire (CW)
Los Angeles, California
www.ChineseWire.com
310.299.1717 Office
Editor@ChineseWire.com

ChineseWire is part of the InvestorBrandNetwork.

Electric technology has come quite a long way since the Tesla Roadster, built using a heavily modified Lotus Elise chassis, first hit the roads more than a decade ago. Electric vehicles (“EVs”) now use dedicated EV platforms, are larger, have bigger batteries and, in many cases, support fast charging. Efforts to increase range by making EVs more efficient, especially regarding to how they use energy, has led car makers to solar energy. Theoretically, solar panels could be used to supplement and even provide power to the onboard battery, giving drivers more range.

The American Solar Challenge is a biennial event that sees participants design, build and then drive solar-powered cars in an endurance challenge across the country. The MIT Solar Electric Vehicle Team were this year’s winners, taking first place after its solar car Nimbus beat eight other cars in the Single Occupancy Vehicle (“SOV”) category. Entirely designed and built by MIT students, Nimbus travelled a whopping 1,109 miles at an average speed of 38.4 miles an hour equipped with a solar array that supplemented the power provided by its battery pack.

This year’s competition was unique; instead of being a timed event, as it has traditionally been for years, it was based on the total distance each entry travelled. The teams had to travel from Independence, Missouri, to Las Vegas, New Mexico, and they were allowed to drive additional miles within each of the race’s three stages as long as their batteries had enough juice. Nimbus, which has been in the making for three years, surpassed the closest runner-up by more than 100 miles.

The MIT team spent three years designing, building and refining its solar vehicle, spending hours upon hours at the MIT Edgerton Center’s machine shop. Test drives included driving Nimbus around the greater-Boston area as well as to Salem, Massachusetts, and even Cape Cod. Team members also drove to Palmer Motorsports Park in Palmer, Massachusetts, in the spring to practice various race components before finally heading to the Formula Sun Grand Prix in Topeka, Arkansas, for the final test runs.

After performing a series of qualifying challenges to qualify for the race, Nimbus placed second after driving 239 laps around the track in three days (597.5 miles). The 2021 American Solar Challenge saw Nimbus travel with a caravan of seven vehicles, including a scout vehicle and a lead car as well as a chase vehicle for the strategy team, a transport truck and trailer, a media car, and a support vehicle carrying food, supplies and camping gear.

Nimbus performed admirably, but the team still has a few glitches to work on. The vehicle’s aerodynamic shape and light weight made it energy efficient, and with adequate sunlight, it could travel up to 40 miles per hour without using energy from the battery. This is the kind of technology that, once perfected, will grant electric vehicles much longer ranges while relying on clean, renewable energy. The next American Solar Challenge will take place in 2022.

The success of the MIT team points to the fact that companies such as Ideanomics Inc. (NASDAQ: IDEX) may soon not have to look very far for investment opportunities since the possibilities in the EV sector are still vastly untapped.

NOTE TO INVESTORS: The latest news and updates relating to Ideanomics Inc. (NASDAQ: IDEX) are available in the company’s newsroom at https://ibn.fm/IDEX

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

• Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange
• Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO
• Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline

Cybin (NEO: CYBN) (NYSE American: CYBN) is wrapping up a highly successful first quarter with the release of its Q1 2021 operational and financial report, for the period ended June 30, 2021 (https://ibn.fm/V9xNp). The biotech company, which is focused on progressing psychedelic therapeutics, hit some milestones this quarter, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than C$120 million, including the C$34 million raised during the company’s latest equity financing round.

“During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space,” said Cybin CEO Doug Drysdale. “We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions. We look forward to sharing updates as we advance our pre-clinical and clinical programs and continue the scientific exploration that we believe will ultimately provide safer and more effective treatments for those suffering with mental illness and addiction issues.”

Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline. The company has started the next phase of its digital therapeutics platform designed to better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for both pre- and postpsychedelic treatments.

Cybin also signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc., a wholly owned subsidiary of Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH), which runs 129 outpatient mental health service centers in the United States. Based on the agreement, Cybin and Greenbrook will establish Mental Health Centers of Excellence that will focus on facilitating research and development of innovative psychedelic compound-based therapeutics for patients suffering from depression.

Finally, Cybin announced that is has begun scaling up its European operations and research activities with several academic and clinical research organizations; the company is also working to transfer its intellectual property assets to its recently formed, wholly owned Ireland subsidiary. The volume of Cybin’s IP is growing as well, with the company’s patent portfolio now numbering 13 filings. Those filings cover novel psychedelic compounds, integration of delivery platforms, methods of use in psychiatric indications, and drug-discovery pipeline of modified and novel ergolines, tryptamines and phenethylamines.

In addition to these key operational highlights, Cybin also posted cash and cash equivalents reaching C$55.1 million for the quarter, boosting the company’s current cash position to C$82.5 million. Those funds are an invaluable resource for the company as it works to progress its clinical pipeline and achieve vital business initiatives. The company is dedicated to revolutionizing mental health care through the use of psychedelic therapeutics and proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.